ESAT-6 proteins: protective antigens and virulence factors?
Priscille Brodin Ida Rosenkrands Peter Andersen Stewart T. Cole Roland Brosch
Trends in Microbiology, 2004
https://doi.org/10.1016/j.tim.2004.09.007
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675
High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. 10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. 10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483
Peter Andersen
Andersen Peter
ORCID: 0000-0002-5869-2551
Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan 10.3389/fimmu.2018.00381
Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein–Based Fusion Antigen CTH522 Into Protein Nanoparticles 10.1016/j.xphs.2018.02.005
High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis 10.3389/fimmu.2017.01973
Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant 10.3389/fimmu.2017.01928
Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis 10.3389/fimmu.2017.01652
A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522 10.1016/j.jconrel.2017.12.003
T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties 10.1016/j.ebiom.2017.12.004
Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses 10.1007/s11095-017-2180-9
PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures 10.1038/mi.2017.67
Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract 10.3389/fimmu.2017.00569
Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes 10.3389/fimmu.2015.00430
Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy 10.4049/jimmunol.1600965
Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6 10.1038/srep45969
Broadening CD4 + and CD8 + T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes 10.1128/jvi.00130-17
Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes 10.1371/journal.pone.0175707
An attenuated Mycobacterium tuberculosis clinical strain with a defect in ESX-1 secretion induces minimal host immune responses and pathology 10.1038/srep46666
Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection 10.1038/s41541-017-0011-y
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial 10.1016/s2213-2600(16)30436-2
The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge 10.1016/j.vaccine.2017.02.020
Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents 10.1093/cid/cix023
Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung 10.1038/mi.2016.70
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials 10.1016/j.vaccine.2017.01.055
Intrauterine inoculation of minipigs with Chlamydia trachomatis during diestrus establishes a longer lasting infection compared to vaginal inoculation during estrus 10.1016/j.micinf.2017.01.008
Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses 10.1038/mi.2016.28
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial 10.1016/j.vaccine.2016.11.023
Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization 10.4049/jimmunol.1600282
Quantitative Protein Profiling ofChlamydia trachomatisGrowth Forms Reveals Defense Strategies Against Tryptophan Starvation 10.1074/mcp.m116.061986
Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants 10.1038/srep39097
Host immunity to Mycobacterium tuberculosis and risk of tuberculosis: A longitudinal study among Greenlanders 10.1016/j.vaccine.2016.09.047
Modulation of Primary Immune Response by Different Vaccine Adjuvants 10.3389/fimmu.2016.00427
Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing 10.1016/j.vaccine.2016.08.039
The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8 + T-cell responses: The immunological consequences of the biodistribution profile 10.1016/j.jconrel.2016.08.034
New tests for detection of Mycobacterium tuberculosis infection: sufficient to meet the WHO 2035 targets? 10.2217/fmb-2016-0131
Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis 10.1371/journal.pone.0161217
Genital tract lesions in sexually mature Göttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D 10.1186/s12917-016-0793-6
PET CT Identifies Reactivation Risk in Cynomolgus Macaques with Latent M. tuberculosis 10.1371/journal.ppat.1005739
Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection 10.1183/13993003.01464-2015
A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ+ CMI responses protects against a genital infection in minipigs 10.1038/icb.2015.79
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children 10.1038/srep22030
The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons 10.1016/j.immuni.2016.02.004
Reprogramming the T Cell Response to Tuberculosis 10.1016/j.it.2015.12.009
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens 10.1038/srep19570
Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis 10.3389/fimmu.2015.00628
Differential Influence of Nutrient-Starved Mycobacterium tuberculosis on Adaptive Immunity Results in Progressive Tuberculosis Disease and Pathology 10.1128/iai.01055-15
Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation 10.1016/j.vaccine.2015.09.024
TB vaccines; promoting rapid and durable protection in the lung 10.1016/j.coi.2015.06.001
Adaptive Immunity againstStreptococcus pyogenesin Adults Involves Increased IFN-γ and IgG3 Responses Compared with Children 10.4049/jimmunol.1500804
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial 10.1016/j.vaccine.2015.05.036
Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach 10.1016/j.jconrel.2015.05.004
Protein Energy Malnutrition during Vaccination Has Limited Influence on Vaccine Efficacy but Abolishes Immunity if Administered during Mycobacterium tuberculosis Infection 10.1128/iai.03030-14
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+T Cells 10.1128/cvi.00092-15
Advanced Vaccine Research Methods for the Decade of Vaccines 10.21775/9781910190036
Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats 10.1016/j.vaccine.2015.02.011
Protection AgainstChlamydia trachomatisInfection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein 10.1093/infdis/jiv137
Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells 10.1016/j.tube.2014.10.005
Protective CD4 T Cells Targeting Cryptic Epitopes of Mycobacterium tuberculosis Resist Infection-Driven Terminal Differentiation 10.4049/jimmunol.1300283
A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4+ T-cell response 10.2217/nnm.14.197
Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease 10.1016/j.vaccine.2010.10.022
An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines 10.1186/s12934-014-0162-8
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human 10.1016/j.vaccine.2014.10.036
Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial 10.1371/journal.pone.0114602
Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model 10.1016/j.vaccine.2013.11.100
High-frequency vaccine-induced CD8+T cells specific for an epitope naturally processed during infection withMycobacterium tuberculosisdo not confer protection 10.1002/eji.201344358
Analysis of protein species differentiation among mycobacterial low-Mr-secreted proteins by narrow pH range Immobiline gel 2-DE-MALDI-MS 10.1016/j.jprot.2013.06.036
Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant 10.1016/j.vaccine.2014.05.050
Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics 10.1073/pnas.1314973111
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 10.1371/journal.pone.0100879
Tuberculosis vaccines – rethinking the current paradigm 10.1016/j.it.2014.04.006
Novel Vaccination Strategies Against Tuberculosis 10.1002/9783527611614.ch31
Novel Vaccination Strategies against Tuberculosis 10.1101/cshperspect.a018523
The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro 10.1039/c3ra42737d
Parasitic infection may be associated with discordant responses to QuantiFERON and tuberculin skin test in apparently healthy children and adolescents in a tuberculosis endemic setting, Ethiopia 10.1186/1471-2334-13-265
Cell-Mediated and Humoral Immune Responses after Immunization of Calves with a Recombinant Multiantigenic Mycobacterium avium subsp. paratuberculosis Subunit Vaccine at Different Ages 10.1128/cvi.05574-11
Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau 10.1089/aid.2013.0076
Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1- IL-2-Secreting Central Memory Cells 10.4049/jimmunol.1300248
Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant 10.1371/journal.pone.0063575
Developing Solid Particulate Vaccine Adjuvants: Surface Bound Antigen Favours a Humoural Response, whereas Entrapped Antigen Shows a Tendency for Cell Mediated Immunity 10.2174/1567201811310030003
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection 10.1016/j.clim.2012.12.005
Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01 10.1016/j.jconrel.2013.01.031
ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination 10.1371/journal.pone.0080579
Bettering BCG: a tough task for a TB vaccine? 10.1038/nm.3153
Comparing Adjuvanted H28 and Modified Vaccinia Virus Ankara Expressing H28 in a Mouse and a Non-Human Primate Tuberculosis Model 10.1371/journal.pone.0072185
Proteomic Profiling ofMycobacterium tuberculosisIdentifies Nutrient-starvation-responsive Toxin–antitoxin Systems 10.1074/mcp.m112.018846
Faculty of 1000 evaluation for Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. 10.3410/f.718016188.793479629
Randomised Clinical Trial Investigating the Specificity of a Novel Skin Test (C-Tb) for Diagnosis of M. tuberculosis Infection 10.1371/journal.pone.0064215
Chlamydia muridarum T Cell Antigens and Adjuvants That Induce Protective Immunity in Mice 10.1128/iai.06338-11
Vaccine-Induced Th17 Cells Are Maintained Long-Term Postvaccination as a Distinct and Phenotypically Stable Memory Subset 10.1128/iai.00550-12
The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection 10.1172/jci46252
Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status 10.1586/erv.12.22
Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses 10.4049/jimmunol.1103183
A structurally informed autotransporter platform for efficient heterologous protein secretion and display 10.1186/1475-2859-11-85
CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice 10.1007/s00262-011-1156-6
A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog 10.1016/j.jconrel.2012.03.016
Deciphering the proteome of the in vivo diagnostic reagent “purified protein derivative” from Mycobacterium tuberculosis 10.1002/pmic.201100544
Immune Responses to ESAT-6 and CFP-10 by FASCIA and Multiplex Technology for Diagnosis of M. tuberculosis Infection; IP-10 Is a Promising Marker 10.1371/journal.pone.0043438
Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection 10.1016/j.jim.2011.05.008
The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity 10.1371/journal.pone.0039909
Increased Immunogenicity and Protective Efficacy of Influenza M2e Fused to a Tetramerizing Protein 10.1371/journal.pone.0046395
The hunt for a global killer 10.4161/hv.20886
A multistage tuberculosis vaccine that confers efficient protection before and after exposure 10.1038/nm.2285
Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers 10.1016/j.vaccine.2010.02.094
Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes 10.1016/j.vaccine.2011.06.040
Validation of the ALS Assay in Adult Patients with Culture Confirmed Pulmonary Tuberculosis 10.1371/journal.pone.0016425
Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens 10.1016/j.vaccine.2011.07.144
Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method 10.1016/j.jconrel.2010.11.021
Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo 10.1007/s11095-010-0301-9
Subunit Vaccines: Distearoylphosphatidylcholine-Based Liposomes Entrapping Antigen Offer a Neutral Alternative to Dimethyldioctadecylammonium-Based Cationic Liposomes as an Adjuvant Delivery System 10.1002/jps.22427
A New Experimental Infection Model in Ferrets Based on AerosolisedMycobacterium bovis 10.4061/2011/981410
CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets 10.1371/journal.pone.0022891
Immune Intervention Strategies against Tuberculosis 10.1128/9781555816872.ch45
Liposomal vaccine delivery systems 10.1517/17425247.2011.558081
Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome Retention Mediates Stronger Th1 Responses 10.1021/mp100208f
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 10.1016/j.vaccine.2011.07.025
Cationic liposomes as vaccine adjuvants 10.1586/14760584.6.5.785
Modulation of Cell Death byM. tuberculosisas a Strategy for Pathogen Survival 10.1155/2011/678570
Detection of bovine tuberculosis in herds with different disease prevalence and influence of paratuberculosis infection on PPDB and ESAT-6/CFP10 specificity 10.1016/j.prevetmed.2010.06.007
Adult-Like Anti-Mycobacterial T Cell and In Vivo Dendritic Cell Responses Following Neonatal Immunization with Ag85B-ESAT-6 in the IC31® Adjuvant 10.1371/journal.pone.0003683
Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31 10.1016/j.vaccine.2006.03.072
Antigenic Equivalence of Human T-Cell Responses to Mycobacterium tuberculosis-Specific RD1-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides 10.1128/iai.68.6.3314-3321.2000
Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose 10.1371/journal.pone.0005930
CD4 and CD8 T-Cell Responses to Mycobacterial Antigens in African Children 10.1164/rccm.200912-1862oc
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime–boost regimen 10.1016/j.vaccine.2009.10.114
Cutting Edge: Mincle Is Essential for Recognition and Adjuvanticity of the Mycobacterial Cord Factor and its Synthetic Analog Trehalose-Dibehenate 10.4049/jimmunol.0904013
First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses 10.4161/hv.6.12.13143
Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared with a Primary Intranasal Infection in a Mouse Genital Challenge Model 10.1371/journal.pone.0010768
Determining Adjuvant Activity on T-Cell Function In Vivo: Th Cells 10.1007/978-1-60761-585-9_15
T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection 10.1111/j.1365-2567.2009.03164.x
Potential role for ESAT6 in dissemination ofM. tuberculosisvia human lung epithelial cells 10.1111/j.1365-2958.2009.06959.x
Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response 10.1016/j.jconrel.2010.03.027
Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen 10.1016/j.jconrel.2009.10.022
Immunological Memory Transferred with CD4 T Cells Specific for Tuberculosis Antigens Ag85B-TB10.4: Persisting Antigen Enhances Protection 10.1371/journal.pone.0008272
Syringe Free Vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles Provides Strong and Prolonged Protection Against Tuberculosis 10.1371/journal.pone.0015043
CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations 10.1016/j.ijpharm.2009.10.043
Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis 10.1002/eji.200939830
Correction: Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis 10.1002/eji.201190009
First-in-Man Open Clinical Trial of a Combined rdESAT-6 and rCFP-10 Tuberculosis Specific Skin Test Reagent 10.1371/journal.pone.0011277
Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection 10.1016/j.tube.2007.11.004
Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status 10.1002/eji.200939856
TB vaccines: current status and future perspectives 10.1038/icb.2009.14
Adjuvanticity of a synthetic cord factor analogue for subunitMycobacterium tuberculosisvaccination requires FcRγ–Syk–Card9–dependent innate immune activation 10.1084/jem.20081445
Signal Regulatory Protein α (SIRPα)+ Cells in the Adaptive Response to ESAT-6/CFP-10 Protein of Tuberculous Mycobacteria 10.1371/journal.pone.0006414
Adjuvants Induce Distinct Immunological Phenotypes in a Bovine Tuberculosis Vaccine Model 10.1128/cvi.00229-09
Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients 10.1371/journal.pone.0005641
Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells 10.4049/jimmunol.0801592
Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique 10.1016/j.tube.2008.09.007
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin 10.1371/journal.pone.0006999
A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells 10.1371/journal.pone.0005771
Distinct Differences in the Expansion and Phenotype of TB10.4 Specific CD8 and CD4 T Cells after Infection with Mycobacterium tuberculosis 10.1371/journal.pone.0005928
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein 10.1016/j.vaccine.2009.09.007
Co-Infection of Cattle withFasciola hepaticaandMycobacterium bovis- Immunological Consequences 10.1111/j.1865-1682.2009.01075.x
Liposome-based cationic adjuvant formulations (CAF): Past, present, and future 10.1080/08982100902726820
Adjuvant properties of a simplified C32 monomycolyl glycerol analogue 10.1016/j.bmcl.2009.02.027
A Simple Mycobacterial Monomycolated Glycerol Lipid Has Potent Immunostimulatory Activity 10.4049/jimmunol.182.1.424
Novel Generation Mycobacterial Adjuvant Based on Liposome-Encapsulated Monomycoloyl Glycerol from Mycobacterium bovis Bacillus Calmette-Guerin 10.4049/jimmunol.0804091
ESAT-6/CFP10 Skin Test Predicts Disease in M. tuberculosis-Infected Guinea Pigs 10.1371/journal.pone.0001978
Ex Vivo Cytokine mRNA Levels Correlate with Changing Clinical Status of Ethiopian TB Patients and their Contacts Over Time 10.1371/journal.pone.0001522
Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis 10.1016/j.tube.2007.12.001
Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants 10.1007/s10456-008-9121-5
PLGA microspheres for the delivery of a novel subunit TB vaccine 10.1080/10611860801900462
Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres 10.1080/10611860802228558
Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells 10.1002/eji.200737889
13 ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13
Liposome Delivery ofChlamydia muridarumMajor Outer Membrane Protein Primes a Th1 Response That Protects against Genital Chlamydial Infection in a Mouse Model1 10.1086/590670
Primary Activation of Antigen-Specific Naive CD4+ and CD8+ T Cells following Intranasal Vaccination with Recombinant Bacteria 10.1128/iai.00793-08
α,α′-trehalose 6,6′-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying 10.1016/j.bbamem.2008.01.013
NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01 10.1016/j.ejpb.2008.07.007
Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection 10.1111/j.1365-2567.2007.02751.x
Detecting a low prevalence of latent tuberculosis among health care workers in Denmark detected by M. tuberculosis specific IFN-γ whole-blood test 10.1080/00365540601148483
PrimaTB STAT-PAK Assay, a Novel, Rapid Lateral-Flow Test for Tuberculosis in Nonhuman Primates 10.1128/cvi.00230-07
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes 10.1111/j.1365-2567.2007.02560.x
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)—A novel adjuvant inducing both strong CMI and antibody responses 10.1016/j.bbamem.2005.10.011
MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis-specific CD4+T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis 10.1111/j.1365-3083.2007.01924.x
Evaluation of Mycobacterium tuberculosis-Specific Antibody Responses in Populations with Different Levels of Exposure from Tanzania, Ethiopia, Brazil, and Denmark 10.1086/520662
Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection 10.4049/jimmunol.178.6.3721
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major 10.1038/nm1592
Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying 10.1016/j.bbamem.2007.05.009
Induction of CD8 T Cells against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and the Presence of a Functional Region of Difference-1 10.4049/jimmunol.179.6.3973
The prognosis of latent tuberculosis: can disease be predicted? 10.1016/j.molmed.2007.03.004
Vaccine strategies against latent tuberculosis infection 10.1016/j.tim.2006.11.008
Tuberculosis vaccines — an update 10.1038/nrmicro1703
The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis 10.1128/iai.01290-06
Optimizing Antigen Cocktails for Detection of Mycobacterium bovis in Herds with Different Prevalences of Bovine Tuberculosis: ESAT6-CFP10 Mixture Shows Optimal Sensitivity and Specificity 10.1128/jcm.01184-06
Immune Responses to Defined Antigens of Mycobacterium bovis in Cattle Experimentally Infected with Mycobacterium kansasii 10.1128/cvi.00054-06
Early Antibody Responses to Experimental Mycobacterium bovis Infection of Cattle 10.1128/cvi.00061-06
A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice 10.1211/jpp.58.6.0009
Identification of CT521 as a Frequent Target of Th1 Cells in Patients with UrogenitalChlamydia trachomatisInfection 10.1086/508203
Tuberculosis in Elephants: Antibody Responses to Defined Antigens of Mycobacterium tuberculosis, Potential for Early Diagnosis, and Monitoring of Treatment 10.1128/cvi.00133-06
Use of Enzyme-Linked Immunospot Assay with Mycobacterium tuberculosis- Specific Peptides for Diagnosis of Recent Infection with M. tuberculosis after Accidental Laboratory Exposure 10.1128/jcm.44.3.1197-1201.2006
Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis 10.1016/j.micinf.2006.03.018
Novel overlapping coding sequences in Chlamydia trachomatis 10.1111/j.1574-6968.2006.00480.x
Prospects for a novel vaccine against tuberculosis 10.1016/j.vetmic.2005.11.030
TB vaccine strategies—What is needed to solve a complex problem? 10.1016/j.tube.2006.01.009
A novel TB vaccine; strategies to combat a complex pathogen 10.1016/s0165-2478(02)00232-8
Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guerin Immunity 10.4049/jimmunol.177.9.6353
The 6-Kilodalton Early Secreted Antigenic Target-Responsive, Asymptomatic Contacts of Tuberculosis Patients Express Elevated Levels of Interleukin-4 and Reduced Levels of Gamma Interferon 10.1128/iai.74.5.2817-2822.2006
Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis 10.1128/cvi.13.2.179-186.2006
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection againstMycobacterium tuberculosis 10.1002/eji.200636128
Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens ofMycobacterium tuberculosis 10.1111/j.1574-695x.2006.00110.x
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model 10.1128/iai.72.10.6148-6150.2004
Assessing the Serodiagnostic Potential of 35 Mycobacterium tuberculosis Proteins and Identification of Four Novel Serological Antigens 10.1128/jcm.43.1.57-65.2005
Antibody Responses in Reindeer (Rangifer tarandus) Infected with Mycobacterium bovis 10.1128/cdli.12.6.727-735.2005
Diagnosis of latentMycobacterium tuberculosisinfection: is the demise of the Mantoux test imminent? 10.1586/14787210.3.6.981
Cationic Liposomes Containing Mycobacterial Lipids: a New Powerful Th1 Adjuvant System 10.1128/iai.73.9.5817-5826.2005
Prospective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis 10.1128/cdli.12.4.491-496.2005
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6 10.1016/j.vaccine.2004.11.051
Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6 10.1128/iai.69.5.2773-2778.2001
Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR 10.1016/j.jim.2005.01.013
Vaccines for Tuberculosis: Novel Concepts and Recent Progress 10.1128/cmr.18.4.687-702.2005
Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 10.4049/jimmunol.174.10.6332
ESAT‐6 and CFP‐10 in Clinical versus Environmental Isolates ofMycobacterium kansasii 10.1086/428950
The success and failure of BCG — implications for a novel tuberculosis vaccine 10.1038/nrmicro1211
TB subunit vaccines—putting the pieces together 10.1016/j.micinf.2005.03.013
Mapping Immune Reactivity toward Rv2653 and Rv2654: Two Novel Low‐Molecular‐Mass Antigens Found Specifically in theMycobacterium tuberculosisComplex 10.1086/381679
Antigen Recognition by Serum Antibodies in White-Tailed Deer (Odocoileus virginianus) Experimentally Infected with Mycobacterium bovis 10.1128/cdli.11.5.849-855.2004
TB diagnosis in non-human primates: comparison of two interferon-γ assays and the skin test for identification of Mycobacterium tuberculosis infection 10.1016/j.vetimm.2004.03.003
Characterization of a Mycobacterium tuberculosis Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles 10.4049/jimmunol.173.3.1966
Reactivation of Tuberculosis During Immunosuppressive Treatment in a Patient with a Positive QuantiFERON®-RD1 Test 10.1080/00365540410015222
The Influence of Remaining Live BCG Organisms in Vaccinated Mice on the Maintenance of Immunity to Tuberculosis 10.1111/j.0300-9475.2004.01471.x
CFP10 discriminates between nonacetylated and acetylated ESAT-6 ofMycobacterium tuberculosis by differential interaction 10.1002/9783527610099.ch8
CFP10 discriminates between nonacetylated and acetylated ESAT-6 ofMycobacterium tuberculosis by differential interaction 10.1002/pmic.200400906
Protein-Protein Interactions of Proteins from the ESAT-6 Family of Mycobacterium tuberculosis 10.1128/jb.186.8.2487-2491.2004
Association of Tuberculin-Boosted Antibody Responses with Pathology and Cell-Mediated Immunity in Cattle Vaccinated with Mycobacterium bovis BCG and Infected with M. bovis 10.1128/iai.72.5.2462-2467.2004
Recognition of ESAT-6 Sequences by Antibodies in Sera of Tuberculous Nonhuman Primates 10.1128/cdli.11.1.222-226.2004
Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines 10.1128/iai.72.3.1608-1617.2004
Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis 10.1086/425931
Healthy Individuals That Control a Latent Infection with Mycobacterium tuberculosis Express High Levels of Th1 Cytokines and the IL-4 Antagonist IL-4 2 10.4049/jimmunol.172.11.6938
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts 10.1164/rccm.200402-232oc
Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection 10.1128/jcm.42.6.2379-2387.2004
PPE Protein (Rv3873) from DNA Segment RD1 of Mycobacterium tuberculosis: Strong Recognition of Both Specific T-Cell Epitopes and Epitopes Conserved within the PPE Family 10.1128/iai.71.11.6116-6123.2003
Genomic Approach to Identification of Mycobacterium bovis Diagnostic Antigens in Cattle 10.1128/jcm.41.8.3719-3728.2003
The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection 10.1007/s00431-003-1199-6
Specific Delayed-Type Hypersensitivity Responses to ESAT-6 Identify Tuberculosis-Infected Cattle 10.1128/jcm.41.5.1856-1860.2003
Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights 10.2174/1389201033377931
Human Th1 Cell Lines Recognize the Mycobacterium tuberculosis ESAT-6 Antigen and its Peptides in Association with Frequently Expressed HLA Class II Molecules 10.1046/j.1365-3083.2003.01204.x
Improved serodetection of Mycobacterium bovis infection in badgers (Meles meles) using multiantigen test formats 10.1016/s0732-8893(03)00046-4
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak 10.1016/s0140-6736(03)12950-9
Use of mycobacterial peptides and recombinant proteins for the diagnosis of bovine tuberculosis in skin test-positive cattle 10.1136/vr.153.20.615
Gamma Interferon Responses Induced by a Panel of Recombinant and Purified Mycobacterial Antigens in Healthy, Non-Mycobacterium bovis BCG-Vaccinated Malawian Young Adults 10.1128/cdli.10.4.602-611.2003
Restoration of mycobacterial antigen-induced proliferation and interferon-γ responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy 10.1016/s0928-8244(03)00166-4
Human T-cell responses to the RD1-encoded protein TB27.4 (Rv3878) from Mycobacterium tuberculosis 10.1111/j.1365-2567.2003.01763.x
Responses of Bovine WC1+   T Cells to Protein and Nonprotein Antigens of Mycobacterium bovis 10.1128/iai.70.11.6114-6120.2002
Effect of different adjuvants on the immune responses of cattle vaccinated with Mycobacterium tuberculosis culture filtrate proteins 10.1016/s0165-2427(02)00017-x
Preparation of Culture Filtrate Proteins from Mycobacterium tuberculosis 10.1385/1-59259-147-7:205
Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene Family 10.1128/iai.70.10.5446-5453.2002
Hypoxic Response of Mycobacterium tuberculosis Studied by Metabolic Labeling and Proteome Analysis of Cellular and Extracellular Proteins 10.1128/jb.184.13.3485-3491.2002
Evaluation of a New Commercial Assay for Diagnosis of Pulmonary and Nonpulmonary Tuberculosis 10.1007/s10096-002-0737-x
Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection with Mycobacterium tuberculosis 10.1128/iai.70.6.3111-3121.2002
Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients 10.1128/jcm.40.2.704-706.2002
Tuberculosis subunit vaccine development: on the role of interferon-γ 10.1016/s0264-410x(00)00519-3
Tuberculosis vaccine development 10.1097/00063198-200205000-00006
Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis 10.1128/iai.70.2.672-678.2002
Specific Acquired Resistance in Mice Immunized with Killed Mycobacteria 10.1046/j.1365-3083.2002.01152.x
A novel TB vaccine; towards a strategy based on our understanding of BCG failure 10.1016/s0264-410x(02)00447-4
Long‐Lived Immune Response to Early Secretory Antigenic Target 6 in Individuals Who Had Recovered from Tuberculosis 10.1086/323044
Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia 10.1128/iai.69.10.6554-6557.2001
Towards more accurate diagnosis of bovine tuberculosis using defined antigens 10.1054/tube.2000.0273
Use of ESAT‐6 and CFP‐10 Antigens for Diagnosis of Extrapulmonary Tuberculosis 10.1086/317663
Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA 10.1016/s0264-410x(01)00109-8
Antigen Discovery and Tuberculosis Vaccine Development in the Post-genomic Era 10.1080/003655401753382639
Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation 10.1046/j.1365-2567.2001.01305.x
Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine 10.1046/j.1365-2567.2001.01244.x
Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research 10.1073/pnas.201404898
Use of ESAT-6 in the interferon-γ test for diagnosis of bovine tuberculosis following skin testing 10.1016/s0378-1135(00)00375-8
Tuberculin Skin Testing Compared with T-Cell Responses to Mycobacterium tuberculosis-Specific and Nonspecific Antigens for Detection of Latent Infection in Persons with Recent Tuberculosis Contact 10.1128/cdli.8.6.1089-1096.2001
TB vaccines: progress and problems 10.1016/s1471-4906(01)01865-8
High Resolution Electroelution of Polyacrylamide Gels for the Purification of Single Proteins from Mycobacterium tuberculosis Culture Filtrate 10.1046/j.1365-3083.2000.00655.x
Diagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10 10.1128/cdli.7.2.155-160.2000
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells 10.1002/1521-4141(200012)30:12<3689::aid-immu3689>3.3.co;2-w
Comparative Evaluation of Low-Molecular-Mass Proteins from Mycobacterium tuberculosis Identifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens 10.1128/iai.68.1.214-220.2000
Mapping and identification ofMycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection 10.1002/(sici)1522-2683(20000301)21:5<935::aid-elps935>3.0.co;2-p
Towards the proteome of Mycobacterium tuberculosis 10.1002/1522-2683(200011)21:17<3740::aid-elps3740>3.3.co;2-v
Assessment of defined antigens for the diagnosis of bovine tuberculosis in skin test-reactor cattle 10.1136/vr.146.23.659
ESAT-6 Subunit Vaccination against Mycobacterium tuberculosis 10.1128/iai.68.2.791-795.2000
Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen 10.1002/1521-4141(200006)30:6<1724::aid-immu1724>3.0.co;2-a
Multiple Epitopes from the Mycobacterium tuberculosis ESAT-6 Antigen Are Recognized by Antigen-Specific Human T Cell Lines 10.1086/313862
Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85 10.1016/s1286-4579(00)01323-x
Tuberculosis vaccines: developmental work and the future 10.1097/00063198-200005000-00007
Detection of Active Tuberculosis Infection by T Cell Responses to Early‐Secreted Antigenic Target 6‐kDa Protein and Culture Filtrate Protein 10 10.1086/315448
CD4+ T-Cell Subsets That Mediate Immunological Memory to Mycobacterium tuberculosis Infection in Mice 10.1128/iai.68.2.621-629.2000
Specific immune-based diagnosis of tuberculosis 10.1016/s0140-6736(00)02742-2
Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins 10.1016/s0928-8244(98)00129-1
Human T Cell Responses to the ESAT‐6 Antigen fromMycobacterium tuberculosis 10.1086/314640
Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree 10.1054/tuld.1999.0206
tuberculin purified protein derivative 10.18578/bnfc.732616164
Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection 10.1046/j.1365-2567.1998.00561.x
Comparison of Antigen-Specific T-Cell Responses of Tuberculosis Patients using Complex or Single Antigens ofMycobacterium tuberculosis 10.1046/j.1365-3083.1998.00419.x
Human cytolytic and interferon  -secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis 10.1073/pnas.95.1.270
Immunity to Mycobacteria with Emphasis on Tuberculosis: Implications for Rational Design of an Effective Tuberculosis Vaccine 10.1159/000058699
A Mycobacterium tuberculosis operon encoding ESAT=6 and a novel low-molecular-mass culture filtrate protein (CFP-10) 10.1099/00221287-144-11-3195
Secreted Antigens and Immune Responses to Mycobacterium tuberculosis 10.1159/000157430
The Potential of the ESAT-6 Antigen Secreted by Virulent Mycobacteria for Specific Diagnosis of Tuberculosis 10.1086/593686
Host Responses and Antigens Involved in Protective Immunity to Mycobacterium tuberculosis 10.1046/j.1365-3083.1997.d01-380.x
Report of the Expert Panel IX Vaccines against tuberculosis 10.1016/s0264-410x(96)90051-1
Key epitopes on the secreted ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis 10.1016/s0165-2478(97)88663-4
The T Cell Response to Secreted Antigens of Mycobacterium tuberculosis 10.1016/s0171-2985(11)80460-2
T Cell Response to Mycobacterium tuberculosis 10.1093/infdis/167.6.1481
Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures 10.1016/0022-1759(93)90195-d
Identification of Immunodominant Antigens during Infection with Mycobacterium tuberculosis 10.1111/j.1365-3083.1992.tb03144.x
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis 10.1016/j.chom.2017.05.012
Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder 10.1016/j.vaccine.2018.04.055
Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C) 10.3389/fimmu.2018.00898
Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System 10.3389/fimmu.2018.00380
Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis 10.1186/1756-0500-6-202
CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination 10.1371/journal.pone.0005139
Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis 10.4049/jimmunol.0900947
A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice 10.1371/journal.pone.0006950
Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements 10.1371/journal.pone.0003116
A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts 10.3389/fimmu.2018.00661
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development 10.3389/fimmu.2017.01203
Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting 10.3389/fimmu.2018.01248
Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine 10.1016/0264-410x(93)90289-a
Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves 10.1371/journal.pone.0201253
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination 10.1056/nejmoa1714021
Dose Optimization of H56:IC31 Vaccine for TB Endemic Populations: A Double-Blind, Placebo-Controlled, Dose-Selection Trial 10.1164/rccm.201802-0366oc
C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial 10.1371/journal.pone.0204554
Concurrent infection with Mycobacterium tuberculosis confers robust protection against secondary infection in macaques 10.1101/403691
Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization 10.3389/fimmu.2018.02825
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo 10.3791/57554
Immunocorrelates of CAF family adjuvants 10.1016/j.smim.2018.10.003
A Liposome Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization 10.1021/acsnano.8b05209
Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial 10.5588/ijtld.18.0137
Diagnostic accuracy of ESAT-6 free IGRA compared to QuantiFERON-TB Gold In-tube 10.1093/cid/ciz034
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection 10.1038/s41385-019-0145-5
Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration 10.1016/j.ejpb.2019.04.020
Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to M. Tuberculosis Infection 10.3389/fimmu.2019.00934
Moving tuberculosis vaccines from theory to practice 10.1038/s41577-019-0174-z
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice 10.1038/s42003-019-0530-3
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial 10.1016/s1473-3099(19)30279-8
Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers 10.1016/j.celrep.2019.07.047
Site-Specific DC Surface Signatures Influence CD4+ T Cell Co-stimulation and Lung-Homing 10.3389/fimmu.2019.01650
Metabolic profiling and compound-class identification reveal alterations in serum triglyceride levels in mice immunized with human vaccine adjuvant Alum 10.1021/acs.jproteome.9b00517
Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles 10.1021/acs.molpharmaceut.9b00908
Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming 10.1016/j.vaccine.2019.10.047
HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen 10.1038/s41598-019-50365-z
Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge 10.1038/s41541-020-0157-x
Roland Brosch
Brosch Roland
ORCID: 0000-0003-2587-3863
Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity. 10.1016/j.chom.2015.05.017
Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii 10.1093/gbe/evv035
Mycobacterial Pathogenomics and Evolution. 10.1128/microbiolspec.MGM2-0025-2013
Release of mycobacterial antigens 10.1111/imr.12251
Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice 10.1128/IAI.02032-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations 10.1038/srep15443
ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection 10.1016/j.tube.2015.02.019
Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
Bovine tubercle bacilli: evolution associated with loss of transmission capacity in humans | Les bacilles de la tuberculose bovine - Une évolution aux dépens de la transmissibilité chez l'homme 10.1051/medsci/20153102003
Mycobacterium tuberculosis Exploits Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection 10.1371/journal.ppat.1003928
Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development 10.2217/fmb.14.70
Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111
Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy 10.1016/j.eururo.2014.02.061
A Specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whiB6 as a novel ESX-1 component 10.1128/IAI.01824-14
A glimpse into the past and predictions for the future: The molecular evolution of the tuberculosis agent 10.1111/mmi.12720
TBCAP; Tuberculosis annotation project 10.1016/j.tube.2012.11.013
Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus 10.1111/mmi.12387
Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis 10.1038/ng.2517
ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169
Characterization of Mycobacterium orygis 10.3201/eid1903.121005
The ESX-5 Associated eccB5-eccC5 Locus Is Essential for Mycobacterium tuberculosis Viability 10.1371/journal.pone.0052059
Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion-encoded PE-PPE proteins predicts vaccine potential 10.1016/j.chom.2012.03.003
Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death 10.1371/journal.ppat.1002507
Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh 10.1371/journal.pone.0040545
Molecular epidemiology of tuberculosis in rural Matlab, Bangladesh 10.5588/ijtld.11.0426
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria 10.1111/j.1462-5822.2012.01799.x
ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells 10.4161/auto.20881
Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation 10.1111/j.1365-2958.2012.08001.x
Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies 10.3201/eid1804.110888
Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis 10.1002/eji.201141548
p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways 10.1074/jbc.M111.223610
Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants 10.1111/j.1462-5822.2010.01565.x
ESAT-6 secretion-independent impact of ESX-1 genes espF and espG 1on virulence of Mycobacterium tuberculosis 10.1093/infdis/jiq089
Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007
Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring 10.1016/j.ejmech.2010.09.048
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling 10.1371/journal.ppat.1001100
Entrapment of intracytosolic bacteria by septin cage-like structures 10.1016/j.chom.2010.10.009
Systematic genetic nomenclature for type VII secretion systems 10.1371/journal.ppat.1000507
Pathogenomics of mycobacteria 10.1159/000235772
Pathogenicity in the tubercle bacillus: Molecular and evolutionary determinants 10.1002/bies.200800191
Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus 10.1371/journal.pone.0005660
Myths and misconceptions: The origin and evolution of Mycobacterium tuberculosis 10.1038/nrmicro2165
Mycobacterial PE, PPE and ESX clusters: Novel insights into the secretion of these most unusual protein families 10.1111/j.1365-2958.2009.06784.x
High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors 10.1371/journal.ppat.1000645
ESX/type VII secretion systems and their role in host-pathogen interaction 10.1016/j.mib.2008.11.003
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis 10.1101/gr.075069.107
Functional analysis of a clonal deletion in an epidemic strain of Mycobacterium bovis reveals a role in lipid metabolism 10.1099/mic.0.2008/022269-0
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
BCG: Molecular history and new perspectives | Le BCG: Histoire moléculaire et nouvelles perspectives RMR-06-2008-25-00-01761-8425-101019-200806495
Genome plasticity of BCG and impact on vaccine efficacy 10.1073/pnas.0700869104
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/JB.00469-07
Pathogenomics: Insights into Tuberculosis and Related Mycobacterial Diseases 10.1002/352760801X.ch10
Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis 10.1093/molbev/msj120
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/IAI.74.1.88-98.2006
Contribution of mycobacterial genomics to the development of innovative strategies against tuberculosis | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses 10.1016/S1773-035X(06)80148-6
"A re-evaluation of M. prototuberculosis": Continuing the debate 10.1371/journal.ppat.0020095
Tuberculosis: From genome to vaccine 10.1586/14760584.4.4.541
Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against Oxidative Stress 10.1074/jbc.M503076200
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin 10.1111/j.1462-5822.2005.00546.x
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans 10.1128/JB.187.5.1668-1676.2005
Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis 10.1371/journal.ppat.0010005
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans 10.1073/pnas.0305877101
Genotypic Analysis of Mycobacterium tuberculosis in Bangladesh and Prevalence of the Beijing Strain 10.1128/JCM.42.2.674-682.2004
ESAT-6 proteins: Protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
Cell Envelope Protein PPE68 Contributes to Mycobacterium tuberculosis RD1 Immunogenicity Independently of A 10-Kilodalton Culture Filtrate Protein and ESAT-6 10.1128/IAI.72.4.2170-2176.2004
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? [3] (multiple letters) 10.1128/JCM.41.3.1345-1348.2003
Royal society of tropical medicine and hygiene meeting at Manson house, London, 18 January 2001: Pathogen genomes and human health. Mycobacterial genomics 10.1016/S0035-9203(02)90222-1
Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis 10.1128/JCM.40.7.2339-2345.2002
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/IAI.70.10.5568-5578.2002
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
The evolution of mycobacterial pathogenicity: Clues from comparative genomics 10.1016/S0966-842X(01)02131-X
Genomics of Mycobacterium bovis 10.1054/tube.2000.0269
Tools for the population genomics of the tubercle bacilli 10.1101/gr.169200
Comparative genomics of the leprosy and tubercle bacilli 10.1016/S0923-2508(00)00117-0
Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays 10.1046/j.1365-2958.1999.01383.x
Analysis of the proteome of Mycobacterium tuberculosis in silico 10.1054/tuld.1999.0220
The high-pathogenicity island of Yersinia pseudotuberculosis can be inserted into any of the three chromosomal asn tRNA genes 10.1046/j.1365-2958.1998.01124.x
Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence 10.1038/31159
Genomic fingerprinting of 80 strains from the WHO multicenter international typing study of Listeria monocytogenes via pulsed-field gel electrophoresis (PFGE) 10.1016/S0168-1605(96)01147-6
Characterization of Listeria strains isolated from soft cheese 10.1016/0168-1605(93)90220-B
Listeriosis outbreak in France in 1992. Microbial data | Epidémie de listériose en France en 1992 aspects microbiologiques 10.1016/S0399-077X(05)81214-4
Use of pulsed field gel electrophoresis to compare large DNA-restriction fragments of Listeria monocytogenes strains belonging to serogroups 1/2 and 3 10.1016/0168-1605(91)90121-5
Subtyping of Listeria monocytogenes serovar 4b by use of low-frequency-cleavage restriction endonucleases and pulsed-field gel electrophoresis 10.1016/0923-2508(91)90080-T
Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions 10.1038/srep17078
Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis 10.1038/srep16918
Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. 10.1016/j.tube.2010.03.008
The BCG Strain Pool: Diversity Matters. 10.1038/mt.2016.18
Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications. 10.1186/s12864-016-2448-1
Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. 10.1111/cmi.12622
Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria 10.1073/pnas.1604921113
Comparative Genomics and Evolution of Mycobacterium bovis BCG 10.1128/9781555817657.ch10
The Mycobacteria: a Postgenomic View 10.1128/9781555815530.ch3
Genomics ofMycobacterium Tuberculosis and Mycobacterium Leprae 10.1002/9781444311433.ch5
Genomics of the Mycobacterium tuberculosis complex and Mycobacterium leprae 10.1002/047001153x.g205204
ESX secretion systems: mycobacterial evolution to counter host immunity 10.1038/nrmicro.2016.131
Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384 10.1128/aac.02509-16
ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. 10.1111/cmi.12726
Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis 10.1038/mi.2016.140
Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection 10.1016/j.celrep.2017.02.057
PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1006399
Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells 10.1038/s41598-017-05878-w
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Evolution of virulence in the Mycobacterium tuberculosis complex 10.1016/j.mib.2017.11.021
The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis 10.3389/fmicb.2017.02284
Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis 10.1038/s41564-017-0090-6
Discovery of the type VII ESX-1 secretion needle? 10.1111/mmi.13579
Identification of genes required forMycobacterium abscessusgrowth in vivo with a prominent role of the ESX-4 locus 10.1073/pnas.1713195115
Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions 10.1073/pnas.1620133114
Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation 10.1371/journal.ppat.1006752
The Biology and Epidemiology of Mycobacterium canettii 10.1007/978-3-319-64371-7_2
Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs 10.2174/1381612819666131118170717
Taxonomic Diversity of Pseudomonads Revealed by Computer-interpretation of Ribotyping Data 10.1016/s0723-2020(96)80026-9
Comparative genomics of the mycobacteria 10.1016/s1438-4221(00)80083-1
Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens 10.3791/50116
Type VII Secretion Systems in Gram-Positive Bacteria 10.1007/82_2015_5015
Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’ 10.1099/mgen.0.000063
Leprosy in red squirrels 10.1126/science.aal0145
CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection 10.1371/journal.ppat.1005770
pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence 10.1038/nmicrobiol.2015.19
A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence ofMycobacterium marinumin multiple hosts 10.1111/cmi.12606
The PE and PPE Protein Families of Mycobacterium tuberculosis 10.1002/9783527611614.ch7
Influence of ESAT-6 Secretion System 1 (RD1) of Mycobacterium tuberculosis on the Interaction between Mycobacteria and the Host Immune System 10.4049/jimmunol.174.6.3570
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo 10.1172/jci84978
Cutting-edge science and the future of tuberculosis control 10.2471/blt.06.035386
ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13
RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139
Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity 10.1093/gbe/evy145
New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach 10.1016/j.jprot.2018.09.013
Update on the virulence factors of the obligate pathogen Mycobacterium tuberculosis and related tuberculosis-causing mycobacteria 10.1016/j.meegid.2018.12.013
Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis 10.1093/gbe/evz162
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902
Mycobacterial virulence: impact on immunogenicity and vaccine research 10.12688/f1000research.20572.1
TbD1 deletion as a driver of the evolutionary success of modern epidemic Mycobacterium tuberculosis lineages 10.1038/s41467-020-14508-5
Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8
ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins 10.1128/microbiolspec.psib-0029-2019
ESX-4, un système de sécrétion mycobactérien ancestral, essentiel pour la croissance de Mycobacterium abscessus dans les phagocytes environnementaux et humains 10.1051/medsci/2018196
Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages 10.1371/journal.ppat.1008069
A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies 10.1126/sciadv.aaz1767
Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential 10.1016/j.ebiom.2020.102761
Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes 10.1073/pnas.2003235117
Le BCG : histoire moléculaire et nouvelles perspectives 10.1016/s0761-8425(08)56032-3
Breaching the phagosome, the case of the tuberculosis agent 10.1111/cmi.13344
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection 10.7554/elife.55692
IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo 10.1128/mSphere.00153-21
ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains 10.1128/mBio.00965-21
Evolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance 10.1128/microbiolspec.tbtb2-0020-2016
Phthiocerol Dimycocerosates From Mycobacterium tuberculosis Increase the Membrane Activity of Bacterial Effectors and Host Receptors 10.3389/fcimb.2020.00420
Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli 10.1038/s41564-021-00938-4
Summary of the Sussex-Huawei locomotion-transportation recognition challenge
Observation of a manifold in the chaotic phase space of an asymmetric optical microcavity
Localized temporal variation of Earth's inner-core boundary from high-quality waveform doublets
Off-axis multi-wavelength dispersion controlling metalens for multi-color imaging
Impact of United States political sanctions on international collaborations and research in Iran